drugset / Trial / NCT05978401
Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open Phase I/II study. The trial consists of two parts, Part1 is a dose-escalation/expansion study, Part2 is a combination of GLS-010 and GLS-010+GLS-012 with standard chemotherapy for advanced non-small-cell lung cancer respectively to assess preliminary efficacy at the combination dose.
Timeline
- Start
- 2023-08-10
- Primary completion
- 2025-04-01
- Completion
- 2026-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BRIVESTOBART | Monoclonal antibody | — | Intravenous |
| Subject | Zimberelimab | Monoclonal antibody | — | Intravenous |
| Background | Carboplatin | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Pemetrexed | Small molecule | — | — |